Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Evolent Health ( (EVH) ) has provided an update.
On June 5, 2025, Evolent Health‘s Board of Directors restructured its committees, appointing Brendan Springstubb to both the Audit and Compensation Committees, as part of a cooperation agreement with Engaged Capital. During the 2025 Annual Meeting, stockholders elected ten directors, ratified Deloitte & Touche LLP as the accounting firm, approved executive compensation for 2024, and amended the 2015 Omnibus Incentive Compensation Plan.
The most recent analyst rating on (EVH) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Evolent Health stock, see the EVH Stock Forecast page.
Spark’s Take on EVH Stock
According to Spark, TipRanks’ AI Analyst, EVH is a Neutral.
Evolent Health demonstrates robust revenue growth and strategic expansions, yet faces challenges in profitability and cash management. Technical indicators suggest bearish trends, and the negative P/E ratio reflects ongoing unprofitability. The positive earnings call provides some optimism but is countered by financial risks and valuation concerns.
To see Spark’s full report on EVH stock, click here.
More about Evolent Health
Evolent Health operates in the healthcare industry, providing services and solutions aimed at improving clinical and financial outcomes for healthcare providers and payers.
Average Trading Volume: 2,357,964
Technical Sentiment Signal: Sell
Current Market Cap: $1B
See more insights into EVH stock on TipRanks’ Stock Analysis page.